0001144204-17-036094.txt : 20170707 0001144204-17-036094.hdr.sgml : 20170707 20170707160345 ACCESSION NUMBER: 0001144204-17-036094 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170706 FILED AS OF DATE: 20170707 DATE AS OF CHANGE: 20170707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taurus4757 GmbH CENTRAL INDEX KEY: 0001603397 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 17955254 BUSINESS ADDRESS: STREET 1: WISSMANNSTRASSE 15 CITY: ZURICH STATE: V8 ZIP: CH 8057 BUSINESS PHONE: 414 43620406 MAIL ADDRESS: STREET 1: WISSMANNSTRASSE 15 CITY: ZURICH STATE: V8 ZIP: CH 8057 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GIRSCHWEILER THOMAS CENTRAL INDEX KEY: 0001273547 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 17955255 4 1 v470493_4.xml OWNERSHIP DOCUMENT X0306 4 2017-07-06 0 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001273547 GIRSCHWEILER THOMAS C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 0 1 0 0001603397 Taurus4757 GmbH ROOSSTRASSE 53 CH-8832 WOLLERAU ZURICH V8 CH 8057 SWITZERLAND 0 0 1 0 Common Stock 2017-07-06 4 A 0 2092 A 2812956 I By Taurus The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter. /s/ Roderick de Greef, as attorney-in-fact for Thomas Girschweiler and Tauras4757 GmbH 2017-07-07